Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands.
HIV Med. 2013 Mar;14(3):176-81. doi: 10.1111/j.1468-1293.2012.01037.x. Epub 2012 Sep 19.
The aim of the study was to gain more insight into the relationship between transmitted singletons found at HIV diagnosis by population sequencing and the possible presence of clinically relevant viral minorities containing additional resistance mutations.
We studied the viral quasispecies and therapy response in 10 individuals with transmitted single nucleoside reverse transcriptase inhibitor (NRTI)-related resistance mutations as detected by population sequencing.
Ultra-deep pyrosequencing did not reveal additional drug-resistance mutations in nine of 10 patients. In these nine patients, no breakthrough with resistant viruses was observed despite the use of low genetic nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens in the majority of patients.
These data suggest that viral minority variants containing additional resistance mutations may be rare in patients with transmitted NRTI singletons in the Netherlands. Larger studies are required to confirm these findings and to determine the therapeutic consequences.
本研究旨在更深入地了解通过群体测序在 HIV 诊断时发现的传播性单核苷酸耐药突变与可能存在的含有其他耐药突变的临床相关病毒亚群之间的关系。
我们研究了通过群体测序检测到的 10 例传播性单核苷逆转录酶抑制剂（NRTI）相关耐药突变的病毒准种和治疗反应。
超深度焦磷酸测序在 10 例患者中的 9 例中未发现额外的耐药突变。在这 9 例患者中，尽管大多数患者使用了低遗传非核苷逆转录酶抑制剂（NNRTI）为基础的方案，但未观察到耐药病毒突破。
这些数据表明，在荷兰传播性 NRTI 单核苷酸患者中，含有额外耐药突变的病毒亚群可能很少见。需要更大的研究来证实这些发现，并确定其治疗后果。
